Pathogen distribution and risk factors of bacterial and fungal infections after liver transplantation.
10.11817/j.issn.1672-7347.2022.220054
- Author:
Xiaoxia WU
1
;
Lingli WU
2
;
Qiquan WAN
3
Author Information
1. Department of Nursing, Third Xiangya Hospital, Central South University, Changsha 410013. 171970473@qq.com.
2. Xiangya School of Nursing, Central South University, Changsha 410013.
3. Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, China. 13548685542@163.com.
- Publication Type:Journal Article
- Keywords:
bacterial infection;
basiliximab;
fungal infection;
liver transplantation;
risk factors
- MeSH:
Bacteria;
Bacterial Infections/etiology*;
Basiliximab;
Communicable Diseases;
End Stage Liver Disease;
Gram-Negative Bacteria;
Gram-Positive Bacteria;
Humans;
Liver Transplantation/adverse effects*;
Mycoses/etiology*;
Risk Factors;
Severity of Illness Index
- From:
Journal of Central South University(Medical Sciences)
2022;47(8):1120-1128
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Liver transplant recipients have a high rate of postoperative infection, and identification of patients at high risk for bacterial and fungal infections will help prevent disease and improve long-term outcomes for them. This study aims to understand the composition, distribution, prognosis of bacterial and fungal infections within 2 months after liver transplantation and to analyze their risk factors.
METHODS:The data of pathogen composition, distribution, and prognosis of bacterial and fungal infections among liver transplant recipients in the Third Xiangya Hospital of Central South University from May 2020 to October 2021 were collected, and the risk factors for these infections were analyzed.
RESULTS:A total of 106 episodes of bacterial or fungal infections occurred in 71.4% of liver transplant recipients (75/105). Gram-negative bacteria were the dominant pathogenic bacteria (49/106, 46.2%), followed by Gram-positive bacteria (31/106, 29.2%). The most common Gram-negative bacterium was Acinetobacter baumannii (13/106, 12.3%). The most common Gram-positive bacterium was Enterococcus faecium (20/106, 18.9%). The most common infections were pulmonary (38/105, 36.2%) and multiple site infections (30/105, 28.6%). Six (6/105, 5.7%) patients with infections died within 2 months after liver transplantation. Univariate analysis showed that the model for end-stage liver disease (MELD) score ≥25, antibiotic use within half a month before transplantation, infections within 2 months prior to transplantation, intraoperative red blood cell infusion≥8 U, indwelling urinary tract catheter ≥4 days after transplantation, and the dosage of basiliximab use ≥40 mg were associated with infections. Multivariate logistic regression analysis revealed that only infections within 2 months prior to transplantation (OR=5.172, 95% CI 1.905-14.039, P<0.01) was an independent risk factor for bacterial and fungal infections after liver transplantation. Postoperative bacterial and fungal infections were reduced in liver transplant recipients receiving basiliximab ≥40 mg (OR=0.197, 95% CI: 0.051-0.762, P<0.05).
CONCLUSIONS:The incidence of bacterial and fungal infections is high in the early stage after liver transplantation, and the mortality after infection is significantly higher than that of non-infected patients. The most common infection is respiratory infection, and the dominant pathogens is Gram-negative bacteria. Patients infected within 2 months prior to liver transplantation are prone to bacterial and fungal infections. Standard use of basiliximab can reduce the incidence of infections after liver transplantation.
